Canakimumab

Ilaris 150 MG/ML Solucion Inyectable

150 mg solución inyectableSpainMarketedAuthorised 23 Jul 2017

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Canakimumab

Ilaris 150 MG/ML Solucion Inyectable

150 mg solución inyectableSpainMarketedAuthorised 23 Jul 2017

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Ilaris 150 mg poeder voor oplossing voor injectieNetherlands · Poeder voor oplossing voor injectie · Novartis Europharm Limited

Ilaris®Serbia · 150mg/mL · rastvor za injekciju · PredstavniŠTvo Novartis Pharma Services INC. Beograd (Novi Beograd)

IlarisSaudi Arabia · NOVARTIS Pharma Stein AG

Ilaris 150MGSaudi Arabia · Novartis

IlarisUnited States · 180MG · injectable · Novartis Pharms

IlarisUnited States · 150MG/ML · Injection · Novartis Pharmaceuticals Corporation

Canakinumab NovartisEuropean Union · Novartis Europharm Limited

Packs

Pack	Code	Status
ILARIS 150 MG/ML SOLUCION INYECTABLE, 1 vial de 1 ml	716850

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Canakimumab
Strength: 150 mg
Dosage form: solución inyectable
Route: vía subcutánea
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 23 Jul 2017
Registration: 109564004
Marketing authorisation holder: Novartis Europharm Limited
Procedure: EU centralised
Supply: Uso Hospitalario